Lv1
54 积分 2023-10-16 加入
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
2天前
已完结
AMP-activated protein kinase: the current landscape for drug development
3天前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
22天前
已完结
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
1个月前
已完结
Molecular modelling study to discover novel JAK2 signaling pathway inhibitor
1个月前
已完结
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
1个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
1个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2个月前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
2个月前
已完结
皖公网安备34019202002308
